All Stories

  1. Community-based tuberculosis screening with computer-aided detection technology alone and in combination with point-of-care C-reactive protein testing: a paired screen-positive trial
  2. Low TB-treatment initiation after positive TB-LAM results
  3. Computer-aided detection thresholds for digital chest radiography interpretation in tuberculosis diagnostic algorithms
  4. Clinical prediction scores to help in the screening of Ebola virus disease suspects
  5. Appropriateness of Antibiotic Prescribing for Acute Conjunctivitis: A Cross-Sectional Study at a Specialist Eye Hospital in Ghana, 2021
  6. Person‐centred care and short oral treatment for rifampicin‐resistant tuberculosis improve retention in care in Kandahar, Afghanistan
  7. Pretomanid for tuberculosis: a systematic review
  8. Long-term retention and predictors of attrition for key populations receiving antiretroviral treatment through community-based ART in Benue State Nigeria: A retrospective cohort study
  9. Development of a risk score to guide targeted hepatitis C testing among human immunodeficiency virus patients in Cambodia
  10. Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial
  11. Predictors of virological failure among people living with HIV receiving first line antiretroviral treatment in Myanmar: retrospective cohort analysis
  12. Diagnostic Accuracy of the INSHI Consensus Case Definition for the Diagnosis of Paradoxical Tuberculosis-IRIS
  13. Case Report: Therapeutic Threshold for Rifampicin-Resistant Tuberculosis in a Patient from Maputo, Mozambique
  14. Human rights: finding the right balance for rifampicin-resistant TB treatment
  15. Finding the right balance between efficacy and tolerability for TB treatment: the search continues
  16. Hepatitis C Prevalence and Validation of a Clinical Prediction Score for Targeted Screening among People Living with HIV in Ghana
  17. Patient-mix, programmatic characteristics, retention and predictors of attrition among patients starting antiretroviral therapy (ART) before and after the implementation of HIV “Treat All” in Zimbabwe
  18. Comparison of first-line tuberculosis treatment outcomes between previously treated and new patients: a retrospective study in Machakos subcounty, Kenya
  19. District-level strategies to control the HIV epidemic in Zimbabwe: a practical example of precision public health
  20. Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study
  21. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study
  22. High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss
  23. Therapeutic threshold for rifampicin-resistant tuberculosis: a case report from Maputo, Mozambique
  24. False Rifampicin Resistance in Xpert Ultra Applied to Lymph Node Aspirate: A Case Report
  25. Challenges to Differentiate Hepatitis C Genotype 1 and 6: Results from A Field-Study in Cambodia
  26. The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
  27. First-line tuberculosis treatment with double-dose rifampicin is well tolerated
  28. Comparison of predictive models for hepatitis C co-infection among HIV patients in Cambodia
  29. High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis
  30. Tuberculosis treatment: one-shot approach or cascade of regimens?
  31. Decision-making in the diagnosis of tuberculous meningitis
  32. Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe’s national antiretroviral therapy programme between 2012 and 2015
  33. The effect of HIV-associated tuberculosis, tuberculosis-IRIS and prednisone on lung function
  34. Time of administration of rabies immunoglobulins and adequacy of antibody response upon post-exposure prophylaxis: a descriptive retrospective study in Belgium
  35. Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe’s National Antiretroviral Therapy Programme between 2012 and 2015
  36. Temporary disengagement and re-engagement in human immunodeficiency virus care in a rural county serving pastoralist communities in Kenya: a retrospective cohort study
  37. Effect of reliance on Xpert MTB/RIF on time to treatment and multidrug-resistant tuberculosis treatment outcomes in Tanzania: a retrospective cohort study
  38. Viral load detection and management on first line ART in rural Rwanda
  39. Performance of algorithms for tuberculosis active case finding in underserved high-prevalence settings in Cambodia: a cross-sectional study
  40. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS
  41. The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy
  42. Development of a clinical prediction score for targeted hepatitis C screening in a low-risk HIV cohort in Cambodia
  43. Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs
  44. What Is the Role of Paired Rapid Plasma Reagin Testing (Simultaneous Testing of Acute and Convalescent Samples) in the Diagnosis of Repeat Syphilis and the Follow-up of Syphilis?
  45. Comment on: Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study
  46. Unexpected Infection with Armillifer Parasites
  47. Ten year experience with antiretroviral treatment in Cambodia: Trends in patient characteristics and treatment outcomes
  48. Rational use of Xpert testing in patients with presumptive TB: clinicians should be encouraged to use the test-treat threshold
  49. A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening
  50. Performance of the Antiretroviral Treatment Program in Ethiopia, 2005-2015: strengths and weaknesses toward ending AIDS
  51. Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia
  52. Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies
  53. Electrolyte and Metabolic Disturbances in Ebola Patients during a Clinical Trial, Guinea, 2015
  54. Diagnosis of Visceral Leishmaniasis Using Peripheral Blood Microscopy in Ethiopia: A Prospective Phase-III Study of the Diagnostic Performance of Different Concentration Techniques Compared to Tissue Aspiration
  55. Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint
  56. Organizing the Donation of Convalescent Plasma for a Therapeutic Clinical Trial on Ebola Virus Disease: The Experience in Guinea
  57. Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial)
  58. CD4 results with a bias larger than hundred cells per microliter can have a significant impact on the clinical decision during treatment initiation of HIV patients
  59. Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014–2015 outbreak
  60. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea
  61. Factors associated with prevalent tuberculosis among patients receiving highly active antiretroviral therapy in a Nigerian tertiary hospital
  62. Usefulness of Common Fibrosis Markers to Predict Viremia in Patients with Reactive Hepatitis C Antibody Test
  63. Brief Report
  64. Systematic screening for drug-resistant tuberculosis with Xpert® MTB/RIF in a referral hospital in Cambodia
  65. Advanced HIV Disease at Enrolment in HIV Care: Trends and Associated Factors over a Ten Year Period in Cambodia
  66. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy
  67. Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study
  68. The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field
  69. Challenges from Tuberculosis Diagnosis to Care in Community-Based Active Case Finding among the Urban Poor in Cambodia: A Mixed-Methods Study
  70. Impact of the Use of a Rapid Diagnostic Test for Visceral Leishmaniasis on Clinical Practice in Ethiopia: A Retrospective Study
  71. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study
  72. Is frontloaded sputum microscopy an option in active tuberculosis case finding?
  73. Atypical manifestations of visceral leishmaniasis in patients with HIV in north Ethiopia: a gap in guidelines for the management of opportunistic infections in resource poor settings
  74. Syphilis reinfections pose problems for syphilis diagnosis in Antwerp, Belgium – 1992 to 2012
  75. Higher rates of metabolic syndrome among women taking zidovudine as compared to tenofovir in rural Africa: preliminary data from the CART-1 study
  76. Clinical aspects of paediatric visceral leishmaniasis in North-west Ethiopia
  77. Active tuberculosis screening of close contacts among the urban poor: a Cambodian experience
  78. A Screen-and-Treat Strategy Targeting Visceral Leishmaniasis in HIV-Infected Individuals in Endemic East African Countries: The Way Forward?
  79. Visceral Leishmaniasis as an AIDS Defining Condition: Towards Consistency across WHO Guidelines
  80. Visceral Leishmaniasis and HIV Coinfection in East Africa
  81. High Parasitological Failure Rate of Visceral Leishmaniasis to Sodium Stibogluconate among HIV Co-infected Adults in Ethiopia
  82. Exploring three approaches to offer distance learning courses through a social network of health researchers in three African countries
  83. Leishmaniasis in immunosuppressed individuals
  84. A Clinical Prediction Score for Targeted Creatinine Testing Before Initiating Tenofovir-Based Antiretroviral Treatment in Cambodia
  85. Bacterial sepsis in patients with visceral leishmaniasis in Northwest Ethiopia
  86. Community-Based Active Tuberculosis Case Finding in Poor Urban Settlements of Phnom Penh, Cambodia: A Feasible and Effective Strategy
  87. Hepatitis B and C Co-Infection among HIV-Infected Adults while on Antiretroviral Treatment: Long-Term Survival, CD4 Cell Count Recovery and Antiretroviral Toxicity in Cambodia
  88. Simplified Clinical Prediction Scores to Target Viral Load Testing in Adults with Suspected First Line Treatment Failure in Phnom Penh, Cambodia
  89. How to improve patient retention in an antiretroviral treatment program in Ethiopia: a mixed-methods study
  90. Scaling up antiretroviral treatment and improving patient retention in care: lessons from Ethiopia, 2005-2013
  91. Bacterial Sepsis in Patients with Visceral Leishmaniasis in Northwest Ethiopia
  92. Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine
  93. Rapid diagnostic tests for neurological infections in central Africa
  94. Validation of a Clinical Prediction Score to Target Viral Load Testing in Adults With Suspected First-Line Treatment Failure in Resource-Constrained Settings
  95. Bloodstream Infection among Adults in Phnom Penh, Cambodia: Key Pathogens and Resistance Patterns
  96. Risk Factors of Treatment-Limiting Anemia after Substitution of Zidovudine for Stavudine in HIV-Infected Adult Patients on Antiretroviral Treatment
  97. Incidence and risk factors for tuberculosis in HIV-infected patients while on antiretroviral treatment in Cambodia
  98. Azithromycin and Ciprofloxacin Resistance in Salmonella Bloodstream Infections in Cambodian Adults
  99. Timing of antiretroviral therapy in Cambodian hospital after diagnosis of tuberculosis: impact of revised WHO guidelines
  100. Short and long term retention in antiretroviral care in health facilities in rural Malawi and Zimbabwe
  101. Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years?
  102. A Clinical Prediction Score in Addition to WHO Criteria for Anti-Retroviral Treatment Failure in Resource-Limited Settings - Experience from Lesotho
  103. Adoption of new HIV treatment guidelines and drug substitutions within first-line as a measure of quality of care in rural Lesotho: health centers and hospitals compared
  104. Staphylococcus aureus blood stream infections in Cambodian adults
  105. Incidence of Treatment-Limiting Toxicity with Stavudine-Based Antiretroviral Therapy in Cambodia: A Retrospective Cohort Study
  106. Is increasing complexity of algorithms the price for higher accuracy? virtual comparison of three algorithms for tertiary level management of chronic cough in people living with HIV in a low-income country
  107. Development and validation of systems for rational use of viral load testing in adults receiving first-line ART in sub-Saharan Africa
  108. Genotypic Impact of Prolonged Detectable HIV Type 1 RNA Viral Load after HAART Failure in a CRF01_AE-Infected Cohort
  109. Melioidosis, Phnom Penh, Cambodia
  110. Determination of Kidney Function Before Tenofovir Initiation: Four-Fold Difference in Need of Tenofovir Dose Reduction Depending on Method Used
  111. Challenges in developing national HIV guidelines: experience from the eastern Mediterranean
  112. Evaluation of the 2007 WHO Guideline to Improve the Diagnosis of Tuberculosis in Ambulatory HIV-Positive Adults
  113. Performance of Abdominal Ultrasound for Diagnosis of Tuberculosis in HIV-Infected Persons Living in Cambodia
  114. A telemedicine service for HIV/AIDS physicians working in developing countries
  115. Time for “Test and Treat” in Prevention of Mother-to-Child Transmission Programs in Low- and Middle-Income Countries
  116. Challenges in the diagnosis of meningitis in low-resource settings
  117. Attrition of HIV-infected individuals not yet eligible for antiretroviral treatment: do we care?
  118. Challenges in HIV and visceral Leishmania co-infection: future research directions
  119. Treatment of HIV infection with drugs for HSV-2 infection – Authors' reply
  120. Combination therapy for visceral leishmaniasis
  121. Treating HIV infection with drugs for HSV-2 infection?
  122. Decrease of vitamin D concentration in patients with HIV infection on a Non Nucleoside Reverse Transcriptase Inhibitor containing regimen
  123. Mobile learning for HIV/AIDS healthcare worker training in resource-limited settings
  124. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings
  125. Substituting nevirapine for efavirenz: risk factors for toxicity in nonnaive patients in a resource-constrained setting
  126. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia
  127. Substituting tenofovir for stavudine in resource-limited settings: there are challenges ahead
  128. Melioidosis in an Urban Referral Hospital, Phnom Penh, Cambodia
  129. Validation of a Manual Blood System and the Distribution of Organisms Causing Bacteremia in a Resource-Limited Setting, SHCH, Phnom Penh, Cambodia
  130. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching
  131. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings
  132. Prevention and treatment of the immune reconstitution inflammatory syndrome
  133. Co-trimoxazole prophylaxis in tropical countries in the era of highly active antiretroviral therapy: do we know enough?
  134. Bridging the gap between clinical practice and diagnostic clinical epidemiology: pilot experiences with a didactic model based on a logarithmic scale
  135. HIV Viral Load Monitoring in Resource‐Limited Regions: Optional or Necessary?
  136. Validation of Primary CD4 Gating as an Affordable Strategy for Absolute CD4 Counting in Cambodia
  137. Remote consultations and HIV/AIDS continuing education in low-resource settings
  138. Authors' reply
  139. The Added Value of a CD4 Count to Identify Patients Eligible for Highly Active Antiretroviral Therapy Among HIV-Positive Adults in Cambodia
  140. Demographic and Clinical Characteristics of HIV-Infected Inpatients and Outpatients at a Cambodian Hospital
  141. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries
  142. Review editorial: Prevention of tuberculosis in resource-poor countries with increasing access to highly active antiretroviral treatment
  143. Comparison of albendazole regimen for prophylaxis of strongyloides hyperinfection in nephrotic syndrome patients on long-term steroids in Cambodia
  144. Palliative care in sub-Saharan Africa
  145. Disseminated nocardiosis presenting with cardiac tamponade in an HIV patient
  146. Highly active antiretroviral treatment in countries with very limited resources: do we have cheaper alternatives?
  147. Do Patents Prevent Access to Drugs for HIV in Developing Countries?
  148. Evaluation of two tests based on the detection of histidine rich protein 2 for the diagnosis of imported Plasmodium falciparum malaria
  149. Clinical algorithm for malaria in Africa